The economics of febrile neutropenia: implications for the use of colony-stimulating factors
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference38 articles.
1. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Int Med 1966, 64, 328–340.
2. Pizzo PA, Hawthorn JW, Heimenz J, et al. A randomized trial comparing cefazidine alone with combination antibiotic therapy in cancer patients with neutropenia and fever. N Engl J Med 1986, 315, 552–558.
3. Gabrilove JL, Jackobowski A, Scher H, et al. Effect of granulocyte colony stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 1988, 318, 1414–1422.
4. Morstyn G, Campbell L, Lieschke G. et al. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 1989, 7, 1554–1562.
5. Filgrastim (r-metHuG-CSF): the first ten years;Welte;Blood,1996
Cited by 172 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Relative dose intensity of taxane-based chemotherapy in breast cancer patients in a tertiary hospital;Journal of Oncology Pharmacy Practice;2023-11-15
2. Clinical implications, safety, efficacy of Recombinant Human Granulocyte Colony-Stimulating Factors and Pegylated Equivalent;Epidemiology, Biostatistics, and Public Health;2022-07-04
3. Management costs of febrile neutropenia in oncology patients in a Tertiary care Hospital Care in Colombia;REV COLOMB CANCEROL;2022
4. Prophylactic use of pegfilgrastim enables the management of severe neutropenia without dose delays in patients with metastatic colorectal cancer treated with TAS‑102 plus bevacizumab;Molecular and Clinical Oncology;2022-04-12
5. Cost-effectiveness of primary prophylaxis of febrile neutropenia with pegfilgrastim in docetaxel, cisplatin and 5-fluorouracil therapy for esophageal cancer;PHARMAZIE;2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3